Aerie Pharmaceuticals Inc (AERI) was Resumed by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $44. Cantor Fitzgerald advised their investors in a research report released on Jun 3, 2016.
Aerie Pharmaceuticals Inc closed down -0.15 points or -0.84% at $17.72 with 2,63,193 shares getting traded on Wednesday. Post opening the session at $17.74, the shares hit an intraday low of $17.36 and an intraday high of $17.8899 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 26, 2016, Gerald D. Cagle (director) purchased 4,646 shares at $18.24 per share price. According to the SEC, on Apr 16, 2015, Anand Mehra (director) sold 425,000 shares at $33.76 per share price.
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.